Targeting a disintegrin and metalloprotease (ADAM) 17-CD122 axis enhances CD8+ T cell effector differentiation and anti-tumor immunity.
Sun L, Jiao A, Liu H, Ding R, Yuan N, Yang B, Zhang C, Jia X, Wang G, Su Y, Zhang D, Shi L, Sun C, Zhang A, Zhang L, Zhang B.
Sun L, et al. Among authors: zhang l, zhang b, zhang c, zhang a, zhang d.
Signal Transduct Target Ther. 2024 Jun 26;9(1):152. doi: 10.1038/s41392-024-01873-6.
Signal Transduct Target Ther. 2024.
PMID: 38918390
Free PMC article.